Atropine/chlorphenamine/pseudoephedrine - MAGNA Pharmaceuticals

Drug Profile

Atropine/chlorphenamine/pseudoephedrine - MAGNA Pharmaceuticals

Alternative Names: Atr/CM/PSE - Magna Pharmaceuticals; Atropine/chlorpheniramine/pseudoephedrine - MAGNA Pharmaceuticals; Atropine/pseudoephedrine/chlorphenamine - MAGNA Pharmaceuticals; Chlorphenamine/atropine/pseudoephedrine - MAGNA Pharmaceuticals; Chlorphenamine/pseudoephedrine/atropine - MAGNA Pharmaceuticals; Chlorpheniramine/pseudoephedrine/atropine - MAGNA Pharmaceuticals; Pseudoephedrine/atropine/chlorphenamine - MAGNA Pharmaceuticals; Pseudoephedrine/chlorphenamine/atropine - MAGNA Pharmaceuticals; StahistRx

Latest Information Update: 21 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MAGNA Pharmaceuticals
  • Class Alkaloids; Antiallergics; Antihistamines; Decongestants; Propanolamines; Pyridines; Small molecules; Tropanes
  • Mechanism of Action Alpha adrenergic receptor agonists; Cholinergic receptor antagonists; Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Seasonal allergic rhinitis

Most Recent Events

  • 21 Jun 2016 No recent reports on development identified - Phase-II for Seasonal allergic rhinitis (In adolescents and adults) in USA (PO)
  • 29 May 2014 MAGNA Pharmaceuticals completes enrolment in its phase II trial for Seasonal allergic rhinitis (In adolescents and adults) in USA (NCT02082054)
  • 31 Mar 2014 Phase-II clinical trials in Seasonal allergic rhinitis (In adolescents and adults) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top